Literature DB >> 8548401

Sub-therapeutic doses of sirolimus and cyclosporin A in combination reduce SLE pathologies in the MRL mouse.

L M Warner1, T Cummons, L Nolan, S N Sehgal.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8548401     DOI: 10.1007/bf01778335

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


× No keyword cloud information.
  7 in total

1.  Delineation of two defects responsible for T-cell hyporesponsiveness to concanavalin A in MRL congenic mice.

Authors:  R Cameron; J D Waterfield
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

2.  Lymphocyte activation. V. Quantitation of the proliferative responses to mitogens using defined T and B cell populations.

Authors:  G Janossy; M F Greaves; M J Doenhoff; J Snajdr
Journal:  Clin Exp Immunol       Date:  1973-08       Impact factor: 4.330

3.  In vitro stimulation of murine spleen cells using a microculture system and a multiple automated sample harvester.

Authors:  D M Strong; A A Ahmed; G B Thurman; K W Sell
Journal:  J Immunol Methods       Date:  1973-04       Impact factor: 2.303

4.  Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin.

Authors:  F J Dumont; M J Staruch; S L Koprak; M R Melino; N H Sigal
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

5.  Immunoregulation in MRL/Mp-lpr/lpr mice: evidence for decreased helper-T-cell and increased suppressor-T-cell function with age.

Authors:  D A Wilson; H Braley-Mullen
Journal:  Cell Immunol       Date:  1982-11-15       Impact factor: 4.868

6.  Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus.

Authors:  L M Warner; L M Adams; S N Sehgal
Journal:  Arthritis Rheum       Date:  1994-02

7.  Deletion of potentially self-reactive T cell receptor specificities in L3T4-, Lyt-2- T cells of lpr mice.

Authors:  B L Kotzin; S K Babcock; L R Herron
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.